In particular, HSPB8 overexpression correlates to high risk of recurrence and metastasis in breast cancer [29], hepatocarcinoma [30–33], and head and neck squamous cell carcinoma [34, 35], while low levels of HSPB8 are associated with negative prognosis in prostate cancer [36, 37]. This evidence concerns the gene HSPB8 and prostate carcinoma.